Publication
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerCutaneous Melanomacivic_curation1.00
- cancerMelanomacivic_curation1.00
- drugTrametinibcivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF Fusioncivic_curation1.00
- variantBRAF Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24345920
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF Fusion2 | ||||||||
| Vemurafenib | Cutaneous MelanomaALIAS | Predictive | D | Supports Resistance | 3 | accepted | EID1416Foundation One NGS assay and targeted RNAseq identified PAPSS1-BRAF fusion in a melanoma sample. Further BRAF fusions (TRIM24-BRAF) were identified in TCGA and additional samples. Ectopic expression o… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC | civic |
| Trametinib | Melanoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID727A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was "pan-negative" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was foun… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC | civic |
| BRAF Fusion2 | ||||||||
| Trametinib | Melanoma | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID726BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This… (full text at CIViC) PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC | civic |
| Vemurafenib | Melanoma | Predictive | D | Supports Resistance | 3 | accepted | EID725BRAF-fusion in "pan-negative" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib. PMID 24345920 · Hutchinson et al., 2013 · Open in CIViC | civic |